MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Research

• Publication date

  2016-09-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1541-7786.MCR-16-0233PMID 27658423PMCID PMC5136335
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MUC1-C drives MYC in multiple myeloma.

  2016cited by this paper
• Hippo pathway and breast cancer stem cells.

  2016influential reference
• Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells

  2016cited by this paper
• Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.

  2016cited by this paper
• Mechanisms of Hippo pathway regulation

  2016influential reference
• Hippo pathway and protection of genome stability in response to DNA damage

  2016influential reference
• MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors

  2016cited by this paper
• The emerging roles of YAP and TAZ in cancer

  2015influential reference
• Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target

  2015cited by this paper
• MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER

  2015cited by this paper
• Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation

  2015cited by this paper
• KRAS and YAP1 converge to regulate EMT and tumor survival.

  2014influential reference
• The Hippo signaling pathway in stem cell biology and cancer

  2014influential reference
• Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells

  2014cited by this paper
• MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition

  2014cited by this paper
• Metabolic characteristics of 13‐cis‐retinoic acid (isotretinoin) and anti‐tumour activity of the 13‐cis‐retinoic acid metabolite 4‐oxo‐13‐cis‐retinoic acid in neuroblastoma

  2014cited by this paper
• MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells

  2014cited by this paper
• Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.

  2014influential reference
• Cross-talk between Wnt/β-catenin and Hippo signaling pathways: a brief review

  2014cited by this paper
• MUC1-C Oncoprotein Activates ERK→C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells*

  2013cited by this paper
• TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS

  2013cited by this paper
• MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

  2013cited by this paper
• The Hippo pathway and human cancer

  2013influential reference
• b-Catenin-Driven Cancers Require a YAP 1 Transcriptional Complex for Survival and Tumorigenesis

  2012influential reference
• MYC on the path to cancer.

  2012influential reference
• A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β‐catenin signalling

  2012influential reference
• MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells*

  2012cited by this paper
• Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells

  2011cited by this paper
• Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.

  2011cited by this paper
• A Monoclonal Antibody Against the Oncogenic Mucin 1 Cytoplasmic Domain

  2011cited by this paper
• The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.

  2011influential reference
• Epithelial cell polarity, stem cells and cancer

  2011influential reference
• Epithelial organization, cell polarity and tumorigenesis.

  2011influential reference
• Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size

  2011influential reference
• The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer?

  2010influential reference
• The hippo signaling pathway in development and cancer.

  2010influential reference
• The Hippo pathway regulates Wnt/beta-catenin signaling.

  2010cited by this paper
• Mucins in cancer: function, prognosis and therapy

  2009cited by this paper
• Epithelial-mesenchymal transitions in development and disease.

  2009influential reference
• MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.

  2009cited by this paper
• Transcriptional regulation of cell polarity in EMT and cancer

  2008influential reference
• MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling

  2007cited by this paper
• The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity

  2007cited by this paper
• MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.

  2007cited by this paper
• Evolution of the human MUC1 oncoprotein.

  2007cited by this paper
• Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62*

  2007cited by this paper
• Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

  2007influential reference
• MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

  2005cited by this paper
• Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.

  2005influential reference
• MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

  2005cited by this paper
• Segregation of receptor and ligand regulates activation of epithelial growth factor receptor

  2003influential reference
• Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and β-Catenin in Cell Adhesion*

  1997cited by this paper
• Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors

  1984cited by this paper

• Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.

  2026cites this paper
• MUC1 in the upper–lower airway inflammatory continuum: an endotype-centered perspective

  2025cites this paper
• PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer

  2025cites this paper
• The Role of MUC1 in Renal Cell Carcinoma

  2024cites this paper
• Role of PATJ in stroke prognosis by modulating endothelial to mesenchymal transition through the Hippo/Notch/PI3K axis

  2024cites this paper
• MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression

  2024cites this paper
• Survival-Associated Cellular Response Maintained in Pancreatic Ductal Adenocarcinoma (PDAC) Switched Between Soft and Stiff 3D Microgel Culture

  2024cites this paper
• Polarity in breast development and cancer.

  2023cites this paper
• Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma.

  2022cites this paper
• The multifaceted role of MUC1 in tumor therapy resistance

  2022influential citation
• Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia

  2022cites this paper
• Advances in MUC1-Mediated Breast Cancer Immunotherapy

  2022cites this paper
• Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells

  2022cites this paper
• Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer

  2022influential citation
• New insights into the organization and regulation of the apical polarity network in mammalian epithelial cells

  2021cites this paper
• Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

  2021cites this paper
• MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

  2021cites this paper
• Transcriptional Control of Apical-Basal Polarity Regulators

  2021cites this paper
• Asynchrony of Apical Polarization, Luminogenesis, and Functional Differentiation in the Developing Thyroid Gland

  2021cites this paper
• Long Non-Coding RNA A2M-AS1 Promotes Breast Cancer Progression by Sponging microRNA-146b to Upregulate MUC19

  2020cites this paper
• In depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-induced colitis.

  2020cites this paper
• MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

  2020cites this paper
• Mucins and their receptors in chronic lung disease

  2020cites this paper
• YAP‑mediated crosstalk between the Wnt and Hippo signaling pathways (Review).

  2020cites this paper
• Muc1-c in chronic inflammation and carcinogenesis;emergence as a target for cancer treatment.

  2020cites this paper
• Regulation of PD-L1 Expression by NF-κB in Cancer

  2020cites this paper
• Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer

  2019cites this paper
• MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

  2019cites this paper
• MUC1-C REPRESSES THE RASSF1A TUMOR SUPPRESSOR IN HUMAN CARCINOMA CELLS

  2019cites this paper
• A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes

  2019cites this paper
• Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer

  2018cites this paper
• Comparative transcriptomics of shear stress treated Pkd1-/- cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease.

  2018cites this paper
• MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

  2018cites this paper
• Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

  2018cites this paper
• MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells

  2018influential citation
• Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer

  2018cites this paper
• A role for bivalent genes in epithelial to mesenchymal transition

  2017cites this paper
• Knockdown of Long Non-Coding RNA KCNQ1OT1 Restrained Glioma Cells’ Malignancy by Activating miR-370/CCNE2 Axis

  2017influential citation
• MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

  2017cites this paper
• MUC1-C ACTIVATES BMI1 IN HUMAN CANCER CELLS

  2016cites this paper